SCHEMBL2433135

SCHEMBL2433135

CC1CCC(C(=O)N(c2cc(-c3ccc(NC(=O)c4cscn4)c(Cl)c3)sc2C(=O)O)C(C)C)CC1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.37
DHODH Q02127 3/20 0.33
IGF2BP2 Q9Y6M1 1/20 0.32
DGAT1 O75907 1/20 0.32
MAPK10 P53779 1/20 0.32
PIM1 P11309 1/20 0.31
PAICS P22234 1/20 0.31
GRM1 Q13255 1/20 0.31
CYP2E1 P05181 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
CDK9 P50750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433123 1.00 GRM4 (0.37) GRM4DHODHIGF2BP2DGAT1MAPK10
SCHEMBL2436809 0.93 GRM4 (0.39) GRM4DHODHMAPK10NPC1RAB9A
SCHEMBL2436807 0.93 GRM4 (0.39) GRM4DHODHMAPK10NPC1RAB9A
SCHEMBL2432584 0.91 GRM4 (0.43) GRM4DHODHDGAT1NPC1RAB9A
SCHEMBL2427859 0.91 GRM4 (0.43) GRM4DHODHDGAT1NPC1RAB9A
SCHEMBL2434761 0.90 GRM4 (0.33) GRM4DHODH
SCHEMBL2434812 0.90 GRM4 (0.33) GRM4DHODH
SCHEMBL2428165 0.89 DGAT1 (0.36) GRM4DGAT1GRM1
SCHEMBL2428166 0.89 DGAT1 (0.36) GRM4DGAT1GRM1
Ammonia Solution, Strong SCHEMBL2432088 0.88 DGAT1 (0.35) GRM4DGAT1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086966-B1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-09-14 EP claimed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US claimed
EP-2086966-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SmithKline Beecham Corporation (US) 2009-08-12 EP claimed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO claimed
EP-2086966-B1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-09-14 EP disclosed
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed
EP-2086966-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SmithKline Beecham Corporation (US) 2009-08-12 EP disclosed
WO-2008059042-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS EIF2AK2, HAVCR2, GTF3C2 GRM4 3141/4885DHODH 1882/4885IGF2BP2 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.